sephin1
AssetAlso IFB-088
Selective inhibitor of PPP1R15A (GADD34) holophosphatase complex, prolonging eIF2alpha phosphorylation and proteostasis
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- PPP1R15A
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2ALS
Phase 2, Completed, NCT05508074, clinicaltrials.gov, 7 Oct 2026
Amyotrophic lateral sclerosis
Phase 2, Completed, NCT05508074, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.